Inhibikase Therapeutics

NasdaqCM:IKT Stock Report

Mkt Cap: US$21.4m

Inhibikase Therapeutics Past Performance

How has Inhibikase Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IKT is currently unprofitable.

Growing Profit Margin: IKT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IKT is unprofitable, and losses have increased over the past 5 years at a rate of 54.2% per year.

Accelerating Growth: Unable to compare IKT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IKT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: IKT has a negative Return on Equity (-63.7%), as it is currently unprofitable.

Discover strong past performing companies